Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by IFP Advisors Inc

IFP Advisors Inc lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 178.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,024 shares of the biopharmaceutical company's stock after buying an additional 656 shares during the period. IFP Advisors Inc's holdings in Regeneron Pharmaceuticals were worth $649,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of REGN. Pinney & Scofield Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. boosted its position in shares of Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares in the last quarter. Tompkins Financial Corp bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $32,000. Curat Global LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $32,000. Finally, American National Bank & Trust bought a new position in Regeneron Pharmaceuticals in the 1st quarter valued at approximately $44,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on REGN shares. Morgan Stanley lowered their price objective on Regeneron Pharmaceuticals from $755.00 to $754.00 and set an "overweight" rating on the stock in a research report on Thursday, July 10th. Cantor Fitzgerald initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 target price for the company. Bank of America decreased their target price on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research note on Thursday, April 17th. BMO Capital Markets decreased their target price on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating for the company in a research note on Monday, June 2nd. Finally, The Goldman Sachs Group decreased their target price on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $837.61.

Regeneron Pharmaceuticals Trading Down 0.3%

Shares of Regeneron Pharmaceuticals stock traded down $1.54 on Friday, hitting $563.10. 755,785 shares of the company traded hands, compared to its average volume of 906,903. The stock's 50 day moving average price is $542.56 and its 200-day moving average price is $609.57. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20. The company has a market cap of $60.79 billion, a PE ratio of 14.34, a PEG ratio of 2.11 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. Regeneron Pharmaceuticals's quarterly revenue was down 3.7% compared to the same quarter last year. During the same period last year, the firm earned $9.55 earnings per share. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.63%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.